Abstract
Acute promyelocytic leukemia (APL) is an interesting model in cancer research, because it can respond to the differentiation/apoptosis induction therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3). Over the past 5 years, it has been well demonstrated that As2O3 induces a high complete remission (CR) rate in both primary and relapsed APL patients (around 85∼90%). The side effects are mild to moderate in relapsed patients, while severe hepatic lesions have been found in some primary cases. After CR obtained in relapsed patients, chemotherapy in combination with As2O3 as post-remission therapy has given better survival than those treated with As2O3 alone. The effect of As2O3 has been shown to be related to the expression of APL-specific PML–RARα oncoprotein, and there is a synergistic effect between As2O3 and ATRA in an APL mouse model. Cell biology studies have revealed that As2O3 exerts dose-dependent dual effects on APL cells. Apoptosis is evident when cells are treated with 0.5∼2.0 μM of As2O3 while partial differentiation is observed using low concentrations (0.1∼0.5 μM) of the drug. The apoptosis-inducing effect is associated with the collapse of mitochondrial transmembrane potentials in a thiol-dependent manner, whereas the mechanisms underlying APL cell differentiation induced by low dose arsenic remain to be explored. Interestingly, As2O3 over a wide range of concentration (0.1∼2.0 μM) induces degradation of a key leukemogenic protein, PML–RARα, as well as the wild-type PML, thus setting up a good example of targeting therapy for human cancers.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agis H, Weltermann A, Mitterbauer G, Thalhammer R, Edelhauser M, Seewann HL, Valent P, Lechner K, Fonatsch C, Geissler K . 1999 Ann. Hematol. 78: 329–332
Akao Y, Nakagawa Y, Akiyama K . 1999 FEBS Lett. 455: 59–62
Andre C, Guillemin MC, Zhu J, Koken MH, Quignon F, Herve L, Chelbi-Alix MK, Dhumeaux D, Wang ZY, Degos L, Chen Z, de Thé H . 1996 Exp. Cell Res. 229: 253–260
Barbui T, Finazzi G, Falanga A . 1998 Blood 91: 3093–3102
Brenner C, Kroemer G . 2000 Science 289: 1150–1151
Cai X, Shen YL, Zhu Q, Jia PM, Yu Y, Zhou L, Huang Y, Zhang JW, Xiong SM, Chen SJ, Wang ZY, Chen Z, Chen GQ . 2000 Leukemia 14: 262–270
Camacho LH, Soignet SL, Chanel S, Ho R, Heller G, Scheinberg DA, Ellison R, Warrell RP . 2000 J. Clin. Onco. 18: 2620–2625
Chen GQ, Zhu J, Shi XG, Ni JH, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z . 1996 Blood 88: 1052–1061
Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de Thé H, Chen SJ, Chen Z . 1997 Blood 89: 3345–3353
Chen YC, Lin-Shiau SY, Lin JK . 1998 J. Cell. Physiol. 177: 324–333
Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY . 2001 Semin. Hematol. 38: 26–36
Cheng GX, Zhu XH, Men XQ, Wang L, Huang QH, Jin XL, Xiong SM, Zhu J, Guo WM, Chen JQ, Xu SF, So E, Chan LC, Waxman S, Zelent A, Chen GQ, Dong S, Liu JX, Chen SJ . 1999 Proc. Natl. Acad. Sci. USA 96: 6218–6223
Cohen MH, Hirschfeld S, Susan FH, Ibrahim A, Johnson JR, O'Leary JJ, White RM, Williams GA, Pazdur R . 2001 Oncologist 6: 4–11
Conrad ME . 1999 N. Engl. J. Med. 340: 1043–1045
Costantini P, Jacotot E, Decaudin D, Kroemer G . 2000a J. Natl. Cancer Inst. 92: 1042–1053
Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G . 2000b Oncogene 19: 307–314
Dai J, Weinberg RS, Waxman S, Jing Y . 1999 Blood 93: 268–277
Deaglio S, Canella D, Baj G, Arnulfo A, Waxman S, Malavasi F . 2001 Leukemia Res. 25: 227–235
Galimberti S, Papineschi F, Carmignani A, Testi R, Fazzi R, Petrini M . 1999 Bone Marrow Transplant 24: 345–348
Gallagher RE . 1998 N. Engl. J. Med. 339: 1389–1391
Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de Thé H . 1998 Blood 91: 4300–4310
Gianni M, de Thé H . 1999 Leukemia 13: 739–749
Huang C, Ma WY, Li J, Dong Z . 1999 Cancer Res. 59: 3053–3058
Huang CH, Chen WJ, Wu CC, Chen YC, Lee YT . 1999 Pacing Clin. Electrophysiol. 22: 965–967
Huang S, Huang CF, Lee T . 2000 Biochem. Pharmacol. 60: 771–780
Huang SY, Chang CS, Tang JL, Tien HF, Kuo TL, Huang SF, Yao YT, Chou WC, Chung CY, Wang CH, Shen MC, Chen YC . 1998 Br. J. Haematol. 103: 1092–1095
Huff J, Chan P, Nyska A . 2000 Toxicol. Sci. 55: 17–23
Jiang XH, Chun-Yu Wong B, Yuen ST, Jiang SH, Cho CH, Lai KC, Lin MC, Kung HF, Lam SK . 2001 Int. J. Cancer 91: 173–179
Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S . 1999 Blood 94: 2102–2111
Jing Y, Wang L, Xia L, Chen GQ, Chen Z, Miller WH, Waxman S . 2001 Blood 97: 264–269
Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y . 2000 Leukemia 14: 431–438
Kitamura K, Yoshida H, Ohno R, Naoe T . 1997 Int. J. Hematol. 65: 179–185
Kitamura K, Minami Y, Yamamoto K, Akao Y, Kiyoi H, Saito H, Naoe T . 2000a Leukemia 14: 1743–1750
Kitamura K, Hoshi S, Koike M, Kiyoi H, Saito H, Naoe T . 2000b Br. J. Haematol. 108: 696–702
Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A, Minard P, Degos L, Varet B, de Thé H . 1999 Oncogene 18: 1113–1118
Kroemer G, de Thé H . 1999 J. Natl. Cancer Inst. 91: 743–745
Kwong, Todd D . 1997 Blood 89: 3487
Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de Thé H . 1999 J. Exp. Med. 189: 1043–1052
Larochette N, Decaudin D, Jacotot E, Brenner C, Marzo I, Susin SA, Zamzami N, Xie Z, Reed J, Kroemer G . 1999 Exp. Cell Res. 249: 413–421
Li YM, Broome JD . 1999 Cancer Res. 59: 776–780
Lin CP, Huang MJ, Chang IY, Lin WY, Sheu YT . 2000a Leuk. Lymphoma 38: 195–198
Lin CP, Huang MJ, Chang IY, Lin WY . 2000b Leuk. Lymphoma 38: 191–194
Look AT . 1998 J. Natl. Cancer Inst. 90: 86–88
McCabe MJ, Singh KP, Reddy SA, Chelladurai B, Pounds JG, Reiners JJ, States JC . 2000 J. Pharmacol. Exp. Ther. 295: 724–733
Melnick A, Licht JD . 2000 Blood 93: 3167–3215
Mervis J . 1996 Science 273: 578
Muller S, Matunis MJ, Dejean A . 1998 EMBO J. 17: 61–70
Niu C, Yan H, Yu T, Sun HP, Liu JX, Li XS, Wu W, Zhang FQ, Chen Y, Zhou L, Li JM, Zeng XY, Yang RR, Yuan MM, Ren MY, Gu FY, Cao Q, Gu BW, Su XY, Chen GQ, Xiong SM, Zhang TD, Waxman S, Wang ZY, Chen SJ . 1999 Blood 94: 3315–3324
Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H, Terada H, Ohno R . 2000 Ann. Intern. Med. 133: 881–885
Ohsawa M, Koyama T, Shibakura M, Kamei S, Hirosawa S . 2000 Leukemia 14: 941–943
Rego EM, He LZ, Warrell RP, Wang ZG, Pandolfi PP . 2000 Proc. Natl. Acad. Sci. USA 97: 10173–10178
Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, Warrell RP, Rafii S . 2000 Blood 96: 1523–1530
Seol JG, Rark WH, Kim ES, Junk CW, Hyun JM, Lee YY, Kim Bk . 2001 Int. J. Oncol. 18: 249–255
Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH . 1998 J. Natl. Cancer Inst. 90: 124–133
Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z . 2001 Leukemia 15: 735–741
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY . 1997 Blood 89: 3354–3360
Shen ZY, Tan LJ, Cai WJ, Shen J, Chen C, Tang XM, Zheng MH . 1999 Int. J. Mol. Med. 4: 33–37
Slack JL, Rusiniak ME . 2000 Ann. Hematol. 79: 227–238
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP . 1998 N. Engl. J. Med. 339: 1341–1348
Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M . 1999 Mol. Cell. Biol. 19: 5170–5178
Sun HD, Ma L, Hu XC, Zhang TD . 1992 Chin. J. Integrat. Chin. Trad. Med. Western Med. 12: 170–171
Tallman MS . 1999 Semin. Thromb. Hemost. 25: 209–215
Tamm I, Paternostro G, Zapata JM . 1998 N. Engl. J. Med. 340: 1043
Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, Goker E . 2000 Clin. Cancer Res. 6: 4957–4964
Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Pandolfi PP . 1998 Blood 92: 1497–1504
Wang ZY, Chen Z . 2000 Lancet Oncol. 1: 101–106
Warrell RP . 1999 Haematologica 84: 75–77
Zhang P, Wang SY, Hu XH . 1996 Chin. J. Hematol. 17: 58–60
Zhang T, Westervelt P, Hess JL . 2000 Mod. Pathol. 13: 954–961
Zhang W, Ohnishi K, Shigeno K, Fujisawa S, Naito K, Nakamura S, Takeshita K, Takeshita A, Ohno R . 1998 Leukemia 12: 1383–1391
Zhu J, Guo WM, Yao YY, Zhao WL, Pan L, Cai X, Ju B, Sun GL, Wang HL, Chen SJ, Chen GQ, Caen J, Chen Z, Wang ZY . 1999 Leukemia 13: 1062–1070
Zhu J, Koken MH, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de Thé H . 1997 Proc. Natl. Acad. Sci. USA 94: 3978–3983
Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y, Tang W, Shi Sun YP, Dai J, Wang ZY, Chen SJ, Zhang TD, Waxman S, Chen Z, GQ . 1999 J. Natl. Cancer Inst. 91: 772–778
Acknowledgements
This work is supported in part by the Chinese National Key Project for Basic Research (973), Chinese National High Tech Program (863), National Natural Science Foundation of China, Samuel Waxman Cancer Research Foundation and Clyde Wu Foundation of Shanghai Institute of Hematology.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zhang, TD., Chen, GQ., Wang, ZG. et al. Arsenic trioxide, a therapeutic agent for APL. Oncogene 20, 7146–7153 (2001). https://doi.org/10.1038/sj.onc.1204762
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204762
Keywords
This article is cited by
-
Arsenic targets Pin1 and cooperates with retinoic acid to inhibit cancer-driving pathways and tumor-initiating cells
Nature Communications (2018)
-
Effects of Arsenic Trioxide on INF-gamma Gene Expression in MRL/lpr Mice and Human Lupus
Biological Trace Element Research (2018)
-
Arsenic trioxide induced rhabdomyolysis, a rare but severe side effect, in an APL patient: a case report
Frontiers of Medicine (2017)
-
Dihydroartemisinin Sensitizes Human Lung Adenocarcinoma A549 Cells to Arsenic Trioxide via Apoptosis
Biological Trace Element Research (2017)
-
Therapeutic Potential of Delivering Arsenic Trioxide into HPV-Infected Cervical Cancer Cells Using Liposomal Nanotechnology
Nanoscale Research Letters (2016)